DermTech, Inc.
DMTKQ Healthcare Diagnostics & Research
DermTech, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.3 million, up 5.36% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow DMTKQ
DermTech, Inc. (DMTKQ) EV/Sales
As of 13 August 2025, DermTech, Inc. (DMTKQ) trades at a EV/Sales of −2.5×. Over the past ten years it has ranged from −6.8× (December 2022) to 220× (February 2021); the current reading is higher than 14% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −0.1× | — |
| FY2022 | −4.9× | — |
| FY2021 | 19.5× | (76.48%) |
| FY2020 | 83.1× | 288.13% |
| FY2019 | 21.4× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | −1.0× | — |
| Dec 2023 | −0.1× | — |
| Sep 2023 | −1.3× | — |
| Jun 2023 | −0.2× | — |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. | −2.5× |
| ISPC iSpecimen Inc. compare | −1.1× |
| BIAF bioAffinity Technologies, Inc. compare | −0.1× |
| XWEL XWELL, Inc. compare | 0.0× |
| ADVB Advanced Biomed Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | 1.4× |
| NOTVQ Inotiv, Inc. compare | 1.6× |
| NDRA ENDRA Life Sciences Inc. compare | 2.2× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)